Semaglutide is a single-agonist activating only the GLP-1 receptor. Tirzepatide is a dual-agonist activating both GLP-1 and GIP receptors, producing greater average weight loss in clinical trials.
Tirzepatide showed ~21% average weight loss (SURMOUNT-1) versus ~15% for semaglutide (STEP-1). Individual results vary.
Compounded semaglutide starts around $99-$149/mo; compounded tirzepatide around $149-$249/mo across providers tracked on GLP1Tally.
Choose semaglutide for a lower-cost entry point. Consider tirzepatide if you want stronger average results and can accommodate the higher cost. Always consult a licensed provider.
GLP1Tally is an independent educational directory. We do not prescribe medications or provide medical advice. All medical consultations and prescriptions are handled independently by licensed third-party providers.